(MEDPAGETODAY) — The FDA issued a message to consumers stating that the evidence does not support the “general” use of aspirin for the primary prevention of heart attacks and strokes.

“In fact, there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain, in situations where the benefit of aspirin for primary prevention has not been established,” the agency said, adding that the benefits of aspirin outweigh the risks in the setting of secondary prevention.

The message came shortly after the FDA denied a request from Bayer to change aspirin’s label to reflect an indication for primary prevention.

Not all organizations agree with the FDA’s stance, however.

Note: Read our discussion guidelines before commenting.